

**Supplemental Table 1
Local Objective Response
(Intent-to-Treat Population)**

Local Objective Response	Celsion-Sponsored Trial N = 11		Duke-Sponsored Trial N = 18		Both Trials Combined N = 29	
None	6	54.5%	9	50.0%	15	51.7%
Partial	4	36.4%	5	27.8%	9	31.0%
Complete	1	9.1%	4	22.2%	5	17.2%
Local objective response in the two trials is not significantly different: P = 0.6317 by exact Wilcoxon-Mann-Whitney test, two-tailed						

Supplemental Table 2

Survival Analysis Summary for the Duke-Sponsored Trial

Efficacy Measure / ThermoDox Dose Level	Failed	Censored	Median (Months)	P-Value¹
Time to Local Progression				0.6396
20 mg/m ²	1	2	4.7	
30 mg/m ²	3	3	4.9	
40 mg/m ²	5	4	5.8	
All Dose Levels	9	9	4.9	
Overall Survival				0.6648
20 mg/m ²	3	0	9.6	
30 mg/m ²	6	0	15.0	
40 mg/m ²	8	1	8.0	
All Dose Levels	17	1	9.0	
Local Progression-Free Survival				0.2510
20 mg/m ²	3	0	7.6	
30 mg/m ²	6	0	4.6	
40 mg/m ²	9	0	4.6	
All Dose Levels	18	0	4.8	

¹ Exact logrank test, two-tailed

Supplemental Table 3

Overall Survival in the Duke-Sponsored Trial (Months)

20 mg/m²	30 mg/m²	40 mg/m²	All Dose Levels
7.6	3.4	1.6	1.6
9.6	6.0	2.3	2.3
44.3	8.3	3.5	3.4
	21.7	5.9	3.5
	23.5	8.0	5.9
	25.3	10.0	6.0
		10.4	7.6
		10.4	8.0
		30.2+	8.3
			9.6
			10.0
			10.4
			10.4
			21.7
			23.5
			25.3
			30.2+
			44.3
Median: 9.6	Median: 15.0	Median: 8.0	Median: 9.0
Overall survival is not significantly different across ThermoDox dose levels: P = 0.6648 by exact logrank test, two-tailed			